reason report
in-lin guidanc catalyst posit
bottom line expect report kick jan
posit catalyst earn achiev
guidanc much lever see upsid well
view pois come least line
fundament initi guidanc buysid expect
also temper md also risk downsid across
earn achiev guidanc given weak birth rate see
cfo transit wild card like line
ebitda guidanc though conif sale updat remain key
stock perform final see downsid risk
fundament guidanc convict remain
highest print medium term well buy
fundament basi like line overal acut
like outperform volum remain weak per
though modestli steeper season high deduct plan
commentari possibl tailwind expect
yoy growth price growth also like remain strong
driven combin case mix intens support
hospit survey payor mix site servic optim medicar
control continu off-set swb opex headwind
behavior continu see challeng fundament length
stay lo reimburs regulatori headwind particularli
pure play uk exposur us headwind
like fare better consensu given sell side estim
come post
mix shift ambulatori site servic continu offer
tailwind uspi ambulatori segment yoy
volum deceler cite hospit survey
steeper season run commerci deduct offer volum
tailwind survey also point particular orthoped procedur
compani inform svb leerink llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
specif tailwind benefit cardiolog also show
procedur specif mix shift
balanc sheet leverag like top mind
investor macro risk rise interest rate
need demonstr solid margin expans cash flow gener
path de-lever beyond get investor
attent asset sale updat toward cash flow import
also diffus fear around variabl debt given exposur interest
rate headwind conif sale gener cash driver
delev also key stock perform
guidanc key initi guidanc
like beat expect addit guidanc
color like also posit catalyst
ss volum trend portfolio ration taper
import catalyst see like disappoint given
fundament headwind dialysi fmr read across
continu behavior headwind particularli exposur
uk md wild card conserv expect like
offer room posit guidanc surpris though see cfo transit
md wild card
op pt expect solid best breed
platform capit deploy drive share gain amid secular volum
headwind also expect posit color initi headlin
ebitda guidanc upsid post mission health close
op pt expect in-lin guidanc uspi
ambulatori platform like outperform given tailwind steeper
season though stock perform heavili depend
conif sale updat path de-lever
op pt expect in-lin guidanc also
like come line sell side view ebitda growth
like beat much temper buy side expect low
mp pt see downsid risk continu
weak uk though may off-set ramp de novo
bed build us also see guidanc also
potenti disappoint continu fundament challeng possibl
conservat recent appoint ceo debra osteen color
departur joey jacob futur take privat investor
mp pt bullish initi guidanc
potenti beat expect turnaround effort
potenti margin expans improv cash flow aco jv
target higher acuiti servic line physician hire updat
last remain asset sale cash flow key stock perform
given variabl debt risk rise interest rate
op pt bullish perform support
survey orthoped aid steeper season
high deduct run volum acceler portfolio ration
taper import stori see potenti better price
growth expect guidanc serv tailwind margin
continu expand turnaround continu
md op pt see like come line given temper
expect alreadi contempl weak birth rate payor mix
headwind anesthesia though cfo transit make hard
anticip guidanc lower ebitda estim
slow margin expans profil line guidanc
op pt see downsid risk ebitda
guidanc given secular dialysi headwind continu turnaround
underpin latest upgrad take longer materi margin
expans lower estim
healthcar facil earn commenc januari report
note coverag yet announc report date follow chart
denot tent date factset
expect report kick jan posit catalyst
earn achiev guidanc much lever see upsid well
view pois come least line fundament initi guidanc
buysid expect also temper md also risk downsid across
earn achiev guidanc given weak birth rate see cfo transit
wild card like line ebitda guidanc though conif sale
updat remain key stock perform final see downsid risk
fundament guidanc convict remain highest print
medium term well buy hold
rel perform acut stock
factset svb leerink llc shade circl repres less downsid risk
fundament basi like line overal acut like
outperform volum remain weak per medacorp hospit util survey flu comp
remain challeng though modestli steeper season high deduct plan
commentari possibl tailwind expect yoy growth price
growth also like remain strong driven combin case mix intens
support hospit survey payor mix site servic optim medicar dsh
reimburs tailwind control continu off-set swb opex headwind
figur mm except ep
leerinkconsensussvb leerinkconsensusguid end facil healtr facil
volum consensu remain soft compar flat upsid
weak flu season though season drive qoq improv believ
best posit due ambulatori build servic line invest geographi secular
pressur like continu though exchang remain rel stabl
svb leerink llc compani report note base svb leerink llc estim
medacorp survey result indic util trend decreas yoy across
inpati ip outpati op emerg depart ed ambulatori surgeri
center trend flat op qoq shift continu
util percentag respond show chang util servic
respond expect chang yoy util respond expect chang variou proceduresorthoped hips/ knee spinecardiologyentgynecologyurologyoth non-trauma healthcar facil
price remain controversi expect strong price driven increas acuiti
optim commerci mix could off-set volum weak continu
normal ss price expect increas averag
believ best posit sustain price due servic line commerci
commentari acuiti price call
clearli intens driver continu focu strateg effort
grow high intens busi drive statist well
give case mix number seen grow pretti consist three
four sometim north past sever quarter realli
function think strategi new capit focu program develop
main driver seen continu grow demand market
drive higher in-pati growth fuel revenu per adjust
admiss number well
similar past quarter deliv strong net revenu per adjust
admiss perform year-over-year basi benefit improv acuiti
across payer better medicar rate stronger portfolio hospit follow
close number divestitur
thoma presid cfo evp
think price continu focu high acuiti item high
acuiti servic line see growth show revenu
thing see er look level one two visit
slightli level four five continu
expect acuiti go drive fair part along manag care
agreement term alreadi negoti feel good price
think said past actual seem make intellectu sens
see rise acuiti acut busi get back
question see ambulatori altern site competit make
sens busi remain acut care hospit higher acuiti
busi level acuiti would therefor sort rise natur
acut care industri gener
think sign think believ also acut care hospit
gener specif focus last sever year
disciplin document clinic effort improv clinic document part
physician hospit think impact well
think element element contribut increas
acuiti know discount
side swb salari wage benefit oper expens
expect improv despit wage pressur due proactiv cost control oper
expens stabil reflect guidanc consensu
behavior continu see challeng fundament lo reimburs
regulatori headwind particularli pure play uk exposur us
headwind like fare better consensu given sell side estim come
compani report us consolid bh adjust fx
report qoq improv volum trend though volum
trend expect moder
compani report svb leerink llc estim
compani report svb leerink llc estim us
note posit side occup rate remain high bh industri driven
overal bed shortag suppli demand dynam remain favor player
add de novo bed capac
believ bh clinic staf shortag continu swb expens key
area focu
compani report svb leerink llc estim
uk ss ebitda margin bp increas pressur staf
shortag premium agenc pay adequ censu stabil
headwind believ see stabil censu ramp uk bed
add season believ lose share though
servic nh may hold referr longer system reach still
staf pressur appear remain hope hire nurs commonwealth nation
appear stall due addit regulatori requir
compani report svb leerink llc estim
compani report svb leerink llc estim
mix shift ambulatori site servic continu offer tailwind
uspi ambulatori segment yoy volum deceler cite
hospit survey steeper season run commerci deduct offer volum
tailwind survey also point particular orthoped procedur specif tailwind benefit
cardiolog also show procedur specif mix shift
balanc sheet leverag like top mind investor macro risk
rise interest rate need demonstr solid margin expans cash flow
gener path de-lever beyond get investor attent
asset sale updat toward cash flow import also diffus fear around
variabl debt given exposur interest rate headwind conif sale gener cash
driver delev also key stock perform
procedur perform ip vs op vs ltm ntminpatientoutpatientfreestand healthcar facil
elev capital-expenditure free cash flow driven tax reform continu level
play field less lever name increas capit
spend plan
tax reform repres ep tailwind less lever name
almost two-third respond show chang capital-expenditure next twelv month
project increas
guidanc mm yoy growthmainten expans bed add jv de novo debt replac hospit spend target capital-expenditure focus higher return core hospit alloc higher percentag capital-expenditure toward addit access point well servic line build-out cardiolog orthoped high-acu reform drove increas cap expans plan increas ad capac improv facil enhanc like elev new marquett mi tower project moder mm year ambulatori capit equip renov new project exist hospit expand er capac technolog construct new rev mainten healthcar facil
major respond show chang capital-expenditure ntm
sameincreas pleas specifi estimatedchang decreas pleas specifi estimatedchang respond expect chang capital-expenditure ntm healthcar facil
guidanc key initi guidanc like beat expect
addit guidanc color like also posit
catalyst ss volum trend portfolio ration taper import catalyst
see like disappoint given fundament headwind dialysi
fmr read across continu behavior headwind particularli exposur
uk see md wild card conserv expect like offer room
posit guidanc surpris though cfo transit md also view wild card
unchangedlessundecidedproperti plant clinic hcit system oper lift oncolog build new cath vinci robot mako hip/kne robot orthoped respond expect categorywis capital-expenditure chang ntm healthcar facil
hospit coverag trade averag consensu ebitda
ebitda estimate ebitda delta guidanc midpoint estimate delta na na md na na na na mean ebitda mm ensussvb leerinkdifferenceensussvb leerinkdifferenceensussvb leerinkdifferenceensussvb leerinkdifferenceensussvb healtr facil
acut coverag trade averag consensu ebitda
expect solid best breed platform capit deploy drive share
gain amid secular volum headwind also expect posit color initi
headlin ebitda guidanc upsid post mission health close posit catalyst
nc attorney gener approv anoth catalyst mission health close
could add upsid includ estim consensu guidanc deal
still requir feder trade commiss ftc approv govern shutdown may delay
approv past expect late januari earli februari close estim anoth
mm ebitda accret time bring mission health margin company-wid
level also announc senior note offer term pend fund
introduc quarterli break maintain ebitda mm
also introduc estim ebitda mm assum ebitda
grow line long-term target rang
consensussvb leerinkconsensussvb leerinkconsensussvb leerinkconsensussvb leerinkrevenu expense/net opex/net rev/ per adj inpati admiss adj admin healthcar facil
note potenti mission health acquisit could tailwind
reflect guidanc consensu valuat mission health could add
ebitda reflect consensu previous state mission health
mm revenu mm annual ebitda
million except per shareiniti guidancerevis leerink estimatesnet ep adjust ss top line growth normal baselin ex-hurricanesmedicar rate increas increas rate mm off-set hurrican michaeloth core trend mm prof liabil changessuppli bp yoy improvementintern uk acquisit savannah ga facil rampok svb leerink ebitda healthcar facil
compani report svb leerink llc estim note mission ebitda accret estim pro forma base
addit mm ebitda accret bring mission health company-wid
margin level mission health current ebitda margin estim
next coupl year could addit mm ebitda accret bring
mission health margin mid-teen
expect in-line guidanc uspi ambulatori platform like
outperform given tailwind steeper season though stock perform
heavili depend conif sale updat path de-lever note
recent announc contract extens sever key manag contract op
ci op op believ
contract posit acut turnaround add upsid ambulatori segment
introduc quarterli break-out estim assum
consolid top line grow ebitda growth opex improv
assum acut price adj admin grow maintain top line growth
ambulatori segment
consensussvb leerinkconsensussvb leerinkconsensussvb leerinkconsensussvb leerinkrevenu expense/net opex/net ni rev/adj admiss inpati admiss equiv admin healthcar facil
mm except per guidanceconsensu svb leerink estimate net earn non-op enseimpair otherloss divest businessadj net incom dilut healthcar facil
mm except per share initi guidanceis guidanc guidanc guidanc guidanc svb leerink estimate net incom cont op earn non-op divest net incom dilut healthcar facil
conif sale remain key controversi manag recent reiter earli
januari still activ consid sale merger spin-off believ hospit
divestitur conif sale ebitda growth provid path de-lever
end
driver termin fee revenuehospit volum growth exclud hurrican impact busi busi ebitda growth driven top line growth margin hurrican impactcost reduct mm mm cost save plan across hospit conif mm execut sever divestitur includ mm pend divestituresconif impact impact hospit divestitur wind health plandeclin ca risk base declin ca risk-bas contractsmalpractic time adjust malpractic hurrican impactca provid declin provid feemedicar medicar dsh acamedicaid tx fl ca provid fee annualizinghit hit svb leerink healthcar facil
expect in-lin guidanc also like come line sell
side view ebitda growth like beat much temper buy side
expect low singl digit
assum ss behavior revenu growth
compani guidanc leerink estimatesconsensusnet revenu adjust ep adjust ebitda net adjust net depreci interest provis incom capital-expenditure driver ebitda ebitda care revenu growth driven volum price fluhenderson continu yoy hendersonbehavior revenu growth hurrican impact net hurrican michael dsh malpractic expenseoth expens improv bp yoy improvementregulatori regulatori censu headwind continu facil closur ramp gulfportprovid lower provid tax yoycambian divest facil svb leerink healthcar facil
see downsid risk continu weak uk though may off-set
ramp de novo bed build us also see guidanc also
potenti disappoint continu fundament challeng possibl conservat recent
appoint ceo debra osteen color departur joey jacob futur take
privat investor radar
provid quarterli break-out estim assum us
trend continu pace moder lo uk assum around
bp improv ss revenu ebitda roughli line consensu
consensussvb leerinkconsensussvb leerinkconsensussvb leerinkconsensussvb oper leas net per patient per patient healthcar facil
compani guidanc compani guidanc compani guidanc compani guidanc leerink leerink ss growth uk ss growth driven volum price includ gradual ramp imd exclus bed addsramp de de novo facil uk censu staf issu continu remain svb leerink healthcar facil
bullish initi guidanc potenti beat expect
turnaround effort potenti margin expans improv cash flow
aco jv target higher acuiti servic line physician hire updat last
remain asset sale cash flow key stock perform given variabl debt risk rise
introduc quarterli break-out estim assum
revenu grow bp margin expans oper effici
assum price grow volum slightli posit partial due stronger
svb leerink llc estim factset
consensussvb leerinkconsensussvb leerinkconsensussvb leerinkconsensussvb leerinkrevenu expense/net opex/net rev/per adj inpati equiv healthcar facil
initi compani guidanc guidanc guidanc guidanc leerink estimatesconsensusnet revenu ebitda adjust admiss outstand amort expens mm interest expens mm driver top line growth line price growth adj volum core divestitur low mid singl digit payment svb leerink healthcar facil
bullish perform support medacorp survey orthoped
aid steeper season high deduct run volum acceler
portfolio ration taper import stori see potenti better price
growth expect guidanc serv tailwind margin continu expand
turnaround continu
compani report factset svb leerink llc estim
compani report factset svb leerink llc estim
consensussvb leerinkconsensussvb leerinkconsensussvb leerinkrevenu expense/net opex/net revenu per svb leerinkrevenu mm mm ebitda mm mm healthcar facil
compani report svb leerink llc estim
driver adjust line top line growth combin price volum nsh nsh acquisitionsg lack hurrican effici swb bp improv lack hurrican effici improv hurrican estimatesancillari ancillari busi includ labsasset under-perform ancillari busi weather case svb leerink ebitda healthcar facil
see like come line given temper expect alreadi contempl weak
birth rate payor mix headwind anesthesia though cfo transit make
hard anticip guidanc lower ebitda estim slow
margin expans profil line guidanc
lower ebitda estim mm mm mm
respect new estim assum bp bp margin expans
consensussvb leerinkconsensussvb leerinkconsensussvb leerinkconsensussvb leerinkrevenu expense/net healthcar facil
guidanceconsensu svb leerinkep ep adjust ss top mm acquisit singl digit marginsphysician pract mm realiz ytdg mm target improv realiz ytd staf wage increas premium pay staf additionssoutheast anesthesia revenu staf headwind contract endingpayor mix headwind anesthesia svb leerink ebitda healthcar facil
see downsid risk ebitda guidanc given secular dialysi
headwind continu turnaround underpin latest upgrad take longer
materi margin expans lower estim
introduc quarterli break-out estim estim
treatment growth acceler margin remain flat
svb leerinkconsensussvb leerinkconsensussvb leerinkconsensussvb leerinkconsensusrevenu growth ebitda less nci ebitda less nci chang leerink consensu ebitda less nci end treatment base guidanc healthcar facil
driver ebitda less nci report ebitda less treatment revenu per treat growth volum volum ramp de novosmircera margin margin improv mircera year transitioncalcimimet rate yoy upsid rate continu one year outsid bundletreat cost wage pressur yoycommerci mix headwind mix stabil contract mm headwind networkintern health increas cost intern health plang initi lobbi lobbi mainli svb leerink ebitda less headwindstailwind healthcar facil
incom statement mm except provis doubt net expensessalari oper total oper depreci incom ebit net interest pbt incom tax incom yoy incom attribut non-controlling net incom attribut net incom attribut share dilut yoy dilut yoy growth growth expense/net opex/net healtr facil
incom statement mm except provis doubt net expensessalari oper total oper ebitda depreci invest ebit net interest pbt incom tax incom yoy incom attribut non-controlling net incom attribut net incom attribut y-o-i chang share million dilut yoy dilut yoy growth expense/net opex/net healar facil
incom provis doubt net expensessalari oper total oper adjust ebitda less ebitda depreci ebit net interest pbt incom tax incom yoy incom attribut non-controlling net incom attribut net incom attribut averag share million dilut yoy dilut yoy non-recur item metricsrevenu growth less nci expense/net opex/net healthcar facil
caresam hospitalsinpati chang patient chang chang length chang caresam hospitalsinpati chang patient chang chang length chang healthcar facil
admiss ss trend
hospit usinpati chang chang chang hospit ukinpati chang chang revenu chang healthcar facil
incom statement mm except provis doubt net expensessalari oper total oper ebitda compani depreci incom ebit net interest pbt incom tax net incom yoy incom attribut non-controlling net incom attribut net incom attribut averag share million dilut yoy dilut yoy growth expense/net opex/net healthcar facil
incom statement mm except expensessalari benefit suppli oper gener administr total oper adjust depreci oper net interest pbt incom tax incom attribut net incom attribut averag share million dilut ep dilut metricsrevenu growth growth opex/net healthcar facil
oper ss trend
incom statement mm except expensespractic salari benefit practic suppli oper gener administr total oper adjust depreci oper net interest pbt incom tax incom attribut md net incom attribut md averag share million dilut yoy dilut yoy growth growth supplies/net healthcar facil
md oper ss trend
incom statement mm except patient servic oper administr ebitda growth ebitda nci margin net incom incom tax less tax net incom attribut growth margin net outstand earn per growth growth healthcar facil
date valuat
primari valuat methodolog base ev/ebitda rel rel
ev/ebitda also track function compani histori hospit group
averag assess potenti ev/ebitda expans next month base
forward forecast contempl underli fundament implic healthcar
reform dcf valuat leverag forward forecast wacc termin
growth rate point potenti multipl expans along sector company-
specif catalyst expect greater potenti multipl expans dcf valuat point
significantli upsid peer current trade level base rate
market perform price target base ev/ebitda
adjust ebitda
downsid risk valuat includ govern payment may face budget cut pressur
risk higher acquisit multipl slow acquisit driven growth foreign currenc exchang
rate fluctuat could materi impact consolid financi posit result oper
uk reli publicli fund entiti unit kingdom revenu
loss reduct fund chang procur method could neg impact
date valuat
pt contempl ev/ebitda ebitda less nci estim
downsid risk valuat includ substanti reduct govern
reimburs lower margin shift patient privat insur provid
medicar govern program advers consequ new on-going litig
regulatori out-of-network contract seek go in-network futur unfavor polici
chang dialysi execut challeng adopt mircera calcimimet
date valuat
price target base pro forma ebitda leverag post transact
debt repay
downsid risk valuat includ possibl delay medicaid expans current
non-expans state delay time sale hospit asset initi improv
physician product expens reduct exposur larg earn swing result
high leverag variou on-going legal proceed may result cash outflow
date valuat
primari valuat methodolog base rel ev/ebitda rel
ev/ebitda track function compani histori hospit group averag
assess potenti ev/ebitda expans next month base forward
forecast contempl underli fundament implic healthcar reform
base rate outperform price target base
ev/ebitda ebitda view
downsid risk valuat includ govern reimburs chang part drug
inpati outpati payment updat possibl legisl judici chang coverag
expans obamacar across medicaid expans exchang contract risk privat
manag plan consolid acceler shift value-bas care
date valuat
rate outperform price target base combin enterpris
valu ebitda multipl valuat base forward forecast contempl underli
fundament implic healthcar reform sum-of-the-part valuat rang
downsid risk valuat includ possibl delay medicaid expans current
non-expans state downsid risk leverag legisl regul cut government
commerci payer reimburs
date valuat
pt contempl ev/ebitda compar histor
takeout multipl ebitda less nci rang
downsid risk valuat includ volum pressur competit econom
headwind medicaid payment may face cut state sponsor face budget pressur
potenti cut medicar physician fee schedul wage inflat could pressur margin
downsid risk leverag
date valuat
primari valuat methodolog base rel ev/ebitda rel
ev/ebitda track function compani histori hospit group averag
assess potenti ev/ebitda expans next month base forward
forecast contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
point potenti multipl expans along sector compani specif
catalyst expect greater potenti multipl expans dcf valuat point
significantli upsid peer current trade level base rate
outperform price target base ev/ebitda
downsid risk valuat includ possibl delay medicaid expans current
non-expans state acut care segment highli concentr la vega texa
cut govern commerci payer reimburs declin receiv collect
rate pay mix pressur behavior segment
date valuat
pt contempl ev/ebitda recent pe takeout
rang physician servic compani given improv visibl margin expans
opportun lack emerg depart ed
downsid risk valuat includ continu shift ambulatori could impact patient
volum pressur birthrat could impact children servic volum continu
anesthesia mix shift medicar could impact margin medicaid payment may face cut
state sponsor face budget pressur potenti cut medicar physician fee schedul
wage inflat could pressur margin revenu could advers affect net loss
